Skip to main content
Have a personal or library account? Click to login
Rejection Surveillance: Integrating Cell-Free DNA and Gene Expression Panels to Decrease Invasiveness in Routine Monitoring of Heart Transplant Recipients Cover

Rejection Surveillance: Integrating Cell-Free DNA and Gene Expression Panels to Decrease Invasiveness in Routine Monitoring of Heart Transplant Recipients

Open Access
|May 2025

References

  1. Copeland H, Knezevic I, Baran DA, et al. Donor heart selection: Evidence-based guidelines for providers. J Heart Lung Transplant. 2023 Jan;42(1):7-29. doi: 10.1016/j.healun.2022.08.030
  2. Briasoulis A, Inampudi C, Pala M, Asleh R, Alvarez P, Bhama J. Induction immunosuppressive therapy in cardiac transplantation: a systematic review and meta-analysis. Heart Fail Rev. 2018 Sep;23(5):641-649. doi: 10.1007/s10741-018-9691-2
  3. Khush KK, Cherikh WS, Chambers DC, et al.; International Society for Heart and Lung Transplantation. The International Thoracic Organ Transplant Registry of the International Society for Heart and Lung Transplantation: Thirty-fifth Adult Heart Transplantation Report-2018; Focus Theme: Multiorgan Transplantation. J Heart Lung Transplant. 2018 Oct;37(10):1155-1168. doi: 10.1016/j.healun.2018.07.022
  4. Caves P, Coltart J, Billingham M, Rider A, Stinson E. Transvenous endomyocardial biopsy--application of a method for diagnosing heart disease. Postgrad Med J. 1975 May;51(595):286-90. doi: 10.1136/pgmj.51.595.286
  5. Crespo-Leiro MG, Zuckermann A, Bara C, et al. Concordance among pathologists in the second Cardiac Allograft Rejection Gene Expression Observational Study (CARGO II). Transplantation. 2012 Dec 15;94(11):1172-7. doi: 10.1097/TP.0b013e31826e19e2
  6. Yilmaz A, Kindermann I, Kindermann M, et al. Comparative evaluation of left and right ventricular endomyocardial biopsy: differences in complication rate and diagnostic performance. Circulation. 2010 Aug 31;122(9):900-9. doi: 10.1161/CIRCULATIONAHA.109.924167
  7. Seferović PM, Tsutsui H, McNamara DM, et al. Heart Failure Association of the ESC, Heart Failure Society of America and Japanese Heart Failure Society Position statement on endomyocardial biopsy. Eur J Heart Fail. 2021 Jun;23(6):854-871. doi: 10.1002/ejhf.2190 Erratum in: Eur J Heart Fail. 2022 Apr;24(4):732. doi: https://doi.org/10.1002/ejhf.2474
  8. Stewart S, Winters GL, Fishbein MC, et al. Revision of the 1990 working formulation for the standardization of nomenclature in the diagnosis of heart rejection. J Heart Lung Transplant. 2005 Nov;24(11):1710-20. doi: 10.1016/j.healun.2005.03.019
  9. Velleca A, Shullo MA, Dhital K, et al. The International Society for Heart and Lung Transplantation (ISHLT) Guidelines for the Care of Heart Transplant Recipients. J Heart Lung Transpl. 2023 May;42(5):e1-141. doi: 10.1016/j.healun.2022.10.015
  10. Miklin DJ, Ravi K, Shekhtman G, et al. Early Use of Donor Derived Cell-Free DNA (dd-cfDNA) in Heart Transplantation. J Heart Lung Transplant. 2022 Apr;41(4):S445. doi: 10.1016/j.healun.2022.01.1124
  11. Saeyeldin A, McKean S, Van Zyl J, Darst V, Hall S. A modern heart transplant rejection surveillance protocol utilizing cell-free DNA: A single-center experience. JHLT Open. 2024 May;4:100076. doi: 10.1016/j.jhlto.2024.100076
  12. Battes LC, Caliskan K, Rizopoulos D, et al. Repeated measurements of NT-pro-B-type natriuretic peptide, troponin T or C-reactive protein do not predict future allograft rejection in heart transplant recipients. Transplantation. 2015 Mar;99(3):580-5. doi: 10.1097/tp.0000000000000378
  13. Moayedi Y, Fan CS, Tinckam KJ, Ross HJ, McCaughan JA. De novo donorspecific HLA antibodies in heart transplantation: do transient de novo DSA confer the same risk as persistent de novo DSA? Clin Transplant. 2018 Nov;32(11):e13416. doi: 10.1111/ctr.13416
  14. Pham MX, Teuteberg JJ, Kfoury AG, et al. Gene-expression profiling for rejection surveillance after cardiac transplantation. N Engl J Med. 2010 May 20;362(20):1890-900. doi: 10.1056/NEJMoa0912965
  15. Crespo-Leiro MG, Stypmann J, Schulz U, et al. Clinical Usefulness of Gene-Expression Profile to Rule Out Acute Rejection after Heart Transplantation: CARGO II. Eur Heart J. 2016 Sep 1;37(33):2591-601. doi: 10.1093/eurheartj/ehv682
  16. Kobashigawa J, Patel J, Azarbal B, et al. Randomized pilot trial of gene expression profiling versus heart biopsy in the first year after heart transplant. Circulation Hear Fail. 2015 May;8(3):557-64. doi: 10.1161/circheartfailure.114.001658
  17. Moayedi Y, Foroutan F, Miller RJH, et al. Risk Evaluation Using Gene Expression Screening to Monitor for Acute Cellular Rejection in Heart Transplant Recipients. J Heart Lung Transpl. 2019 Jan;38(1):51-8. doi: 10.1016/j.healun.2018.09.004
  18. FDA [Internet]. Silver Spring, MD: US Food and Drug Administration; c2025. Cardiac Allograft Gene Expression Profiling Test System – Class II special Controls Guidance for Industry and FDA; 2009 Oct 21 [cited 2025 Mar 23]. Available from: https://www.fda.gov/medical-devices/guidance-documents-medical-devices-and-radiation-emitting-products/cardiac-allograft-gene-expression-profiling-test-systems-class-ii-special-controls-guidance-industry
  19. DeVlaminck I, Valantine HA, Snyder TM, et al. Circulating cell-free DNA enables noninvasive diagnosis of heart transplant rejection. Sci Transl Med. 2014 Jun 18;6(241):241ra77. doi: 10.1126/scitranslmed.3007803
  20. Agbor-Enoh S, Shah P, Tunc I, et al. Cell-free DNA to detect heart allograft acute rejection. Circulation. 2021 Mar 23;143(12):1184-97. doi: 10.1161/circulationaha.120.049098
  21. Khush KK, Patel J, Pinney S, et al. Noninvasive detection of graft injury after heart transplant using donor-derived cell-free DNA: a prospective multicenter study. Am J Transplant. 2019 Oct;19(10):2889-99. doi: 10.1111/ajt.15339
  22. Kim PJ, Olymbios M, Siu A, et al. A novel donorderived cell-free DNA assay for the detection of acute rejection in heart transplantation. J Hear Lung Transplant. 2022 Jul;41(7):919-27. doi: 10.1016/j.healun.2022.04.002
  23. Henricksen EJ, Moayedi Y, Purewal S, et al. Combining donor derived cell free DNA and gene expression profiling for noninvasive surveillance after heart transplantation. Clin Transplant. 2023 Mar;37(3):e14699. doi: 10.1111/ctr.14699
  24. Grskovic M, Hiller DJ, Eubank LA, et al. Validation of a Clinical-Grade Assay to Measure Donor-Derived Cell-Free DNA in Solid Organ Transplant Recipients. J Mol Diagn. 2016 Nov;18(6):890-902. doi: 10.1016/j.jmoldx.2016.07.003
  25. Holzhauser L, DeFilippis EM, Nikolova A, et al. The End of Endomyocardial Biopsy?: A Practical Guide for Noninvasive Heart Transplant Rejection Surveillance. JACC Heart Fail. 2023 Mar;11(3):263-276. doi: 10.1016/j.jchf.2022.11.002
  26. Nikolova A, Agbor-Enoh S, Bos S, et al. European Society for Organ Transplantation (ESOT) Consensus Statement on the Use of noninvasive Biomarkers for Cardiothoracic Transplant Rejection Surveillance. Transpl Int. 2024 Jun 11;37:12445. doi: 10.3389/ti.2024.12445
  27. DePasquale EC, Ardehali A. Primary graft dysfunction in heart transplantation. Curr Opin Organ Transplant. 2018 Jun;23(3):286-294. doi: 10.1097/MOT.0000000000000523
  28. Badano LP, Miglioranza MH, Edvardsen T, et al.: Document reviewers. European Association of Cardiovascular Imaging/Cardiovascular Imaging Department of the Brazilian Society of Cardiology recommendations for the use of cardiac imaging to assess and follow patients after heart transplantation. Eur Heart J Cardiovasc Imaging. 2015 Sep;16(9):919-48. doi: 10.1093/ehjci/jev139
  29. Mena C, Wencker D, Krumholz HM, McNamara RL. Detection of Heart Transplant Rejection in Adults by Echocardiographic Diastolic Indices: A Systematic Review of the Literature. J Am Soc Echocardiogr. 2006 Oct;19(10):1295-300. doi: 10.1016/j.echo.2006.04.029
  30. Mingo-Santos S, Moñivas-Palomero V, Garcia-Lunar I, et al. Usefulness of Two-Dimensional Strain Parameters to Diagnose Acute Rejection after Heart Transplantation. J Am Soc Echocardiogr. 2015 Oct;28(10):1149-56. doi: 10.1016/j.echo.2015.06.005
  31. Messroghli DR, Moon JC, Ferreira VM, et al. Clinical recommendations for cardiovascular magnetic resonance mapping of T1, T2, T2* and extracellular volume: A consensus statement by the Society for Cardiovascular Magnetic Resonance (SCMR) endorsed by the European Association for Cardiovascular Imaging (EACVI). J Cardiovasc Magn Reson. 2017 Oct 9;19(1):75. doi: 10.1186/s12968-017-0389-8. Erratum in: J Cardiovasc Magn Reson. 2018 Feb 7;20(1):9. doi: https://doi.org/10.1186/s12968-017-0408-9
  32. Han D, Miller RJH, Otaki Y, et al. Diagnostic Accuracy of Cardiovascular Magnetic Resonance for Cardiac Transplant Rejection: A Meta-Analysis. JACC Cardiovasc Imaging. 2021 Dec;14(12):2337-2349. doi: 10.1016/j.jcmg.2021.05.008
  33. Anthony C, Imran M, Pouliopoulos J, et al. Cardiovascular Magnetic Resonance for Rejection Surveillance After Cardiac Transplantation. Circulation. 2022 Jun 21;145(25):1811-1824. doi: 10.1161/CIRCULATIONAHA.121.057006
  34. Sciaccaluga C, Ghionzoli N, Mandoli GE, et al. The role of noninvasive imaging modalities in cardiac allograft vasculopathy: an updated focus on current evidences. Heart Fail Rev. 2022 Jul;27(4):1235-1246. doi: 10.1007/s10741-021-10155-0
  35. Prasad N, Harris E, DeFilippis EM, et al. PET/CT with Myocardial Blood Flow Assessment Is Prognostic of Cardiac Allograft Vasculopathy Progression and Clinical Outcomes. J Nucl Med. 2025 Feb 3;66(2):264-270. doi: 10.2967/jnumed.124.268713
  36. Bravo PE, Bergmark BA, Vita T, et al. Diagnostic and prognostic value of myocardial blood flow quantification as noninvasive indicator of cardiac allograft vasculopathy. Eur Heart J. 2018 Jan 21;39(4):316-323. doi: 10.1093/eurheartj/ehx683
DOI: https://doi.org/10.14797/mdcvj.1578 | Journal eISSN: 1947-6108
Language: English
Page range: 51 - 57
Submitted on: Jan 31, 2025
Accepted on: Mar 11, 2025
Published on: May 15, 2025
Published by: Houston Methodist DeBakey Heart & Vascular Center
In partnership with: Paradigm Publishing Services

© 2025 Hatem Alansari, Janardhana R. Gorthi, published by Houston Methodist DeBakey Heart & Vascular Center
This work is licensed under the Creative Commons Attribution-NonCommercial 4.0 License.